GSK suspends Entereg development
Executive Summary
Following a cardiovascular signal in a Phase III safety study of Entereg, GSK and Adolor are stopping development of alvimopan for treatment of opioid-induced bowel dysfunction, the companies say April 9. Similar to results from an interim analysis released in November, the study shows an increase in myocardial infarctions and all serious cardiovascular events for patients receiving alvimopan compared to placebo. However, the firms continue to pursue approval for a postoperative ileus indication that received an "approvable" letter in November...
You may also be interested in...
Entereg advisory committee
FDA's Gastrointestinal Drugs Advisory Committee will review the NDA for GlaxoSmithKline/Adolor's µ-opioid receptor agonist Entereg for treatment of postoperative ileus following partial or small bowel resection surgery with primary anastomosis Jan. 23, 2008. The meeting will likely address a cardiovascular safety signal identified in a Phase III study, which led to the suspension of development of the new molecular entity for opioid-induced bowel dysfunction (1"The Pink Sheet" April 16, 2007, In Brief). The postoperative ileus indication for Entereg (alvimopan), which has received two "approvable letters," has a Feb. 10, 2008, user fee date...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.